Jun-Ying Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jun-Ying Chen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- BaoQing Chen
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center
1 shared publication - Biqi Chen
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Reasearch Center for Cancer, Sun Yat-sen University Cancer Center, Guangdong Esophageal Cancer Institute, Guangzhou, Guangdong, China
1 shared publication Chang-Sen Leng
Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China
1 shared publication- Changsen Leng
Department of Thoracic Oncology Sun Yat‐sen University Cancer Center Guangzhou China
1 shared publication Chen Yi
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Reasearch Center for Cancer, Sun Yat-sen University Cancer Center, Guangdong Esophageal Cancer Institute, Guangzhou, Guangdong, China
1 shared publicationHan Yang
Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 12 January 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (1) , e013065
Serum cytokines predict response and survival in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD-1 antibody: analyses of two phase II clinical trials
Purpose: Chemoradiotherapy (CRT) combined with anti-PD-1 for locally advanced esophageal squamous cell carcinoma (ESCC) has shown promising efficacy but lack the predictive biomarkers to identify patients who could benefit from this therapy. The predictive value of serum cytokines in ESCC patients remains unclear. We aimed to identify cytokine-based biomarkers for treatment response and survival in this setting. Experimental Design: Exploratory analyses were conducted on 81 ESCC patients from two phase II trials treated with CRT plus toripalimab, with validation in an independent prospective cohort (n=61). Nineteen serum cytokines were assessed at baseline, during, and post-CRT plus anti-PD-1 antibody. A cytokine-based risk score model (CYTOscore) was constructed. Multi-omics profiling including RNA-seq, WES, and spatial transcriptomics were performed to explore potential differences in tumor microenvironments. Results: Cox analyses identified Interleukin-8 (IL-8), C-C motif chemokine ligand 3 (CCL3), and C-C motif chemokine ligand 4 (CCL4) as potential biomarkers and were used to constructed the CYTOscore. Patients stratified by baseline CYTOscore showed significantly longer OS (HR, 0.31; 95%CI, 0.16-0.62; p= 0.00045) and PFS (HR, 0.33; 95%CI, 0.17-0.62; p= 0.00036) in the low-risk group, which also had higher complete response (CR) rates (66% vs 35%, p=0.014). These finding were next validated in the external cohort, with the low-risk group demonstrating higher CR rates (66% vs 27%, p=0.039) and longer OS (HR 0.30, 95% CI 0.09-0.99, p=0.045). A nomogram incorporating baseline CYTOscore and clinical characteristics showed promising predictive accuracy in 1-, 2-, and 3-year OS (AUC=0.77, 0.78, and 0.76). Multi-omics analysis revealed enriched interferon-γ/α signaling in B cells within low-risk patients. Conclusions: The CYTOscore based on IL-8, CCL3, and CCL4 effectively predicts treatment response and survival in ESCC patients receiving CRT plus anti-PD-1 antibody.
- 12 January 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (1) , e013065
Open AccessSerum cytokines predict response and survival in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD-1 antibody: analyses of two phase II clinical trials
Purpose: Chemoradiotherapy (CRT) combined with anti-PD-1 for locally advanced esophageal squamous cell carcinoma (ESCC) has shown promising efficacy but lack the predictive biomarkers to identify patients who could benefit from this therapy. The predictive value of serum cytokines in ESCC patients remains unclear. We aimed to identify cytokine-based biomarkers for treatment response and survival in this setting. Experimental Design: Exploratory analyses were conducted on 81 ESCC patients from two phase II trials treated with CRT plus toripalimab, with validation in an independent prospective cohort (n=61). Nineteen serum cytokines were assessed at baseline, during, and post-CRT plus anti-PD-1 antibody. A cytokine-based risk score model (CYTOscore) was constructed. Multi-omics profiling including RNA-seq, WES, and spatial transcriptomics were performed to explore potential differences in tumor microenvironments. Results: Cox analyses identified Interleukin-8 (IL-8), C-C motif chemokine ligand 3 (CCL3), and C-C motif chemokine ligand 4 (CCL4) as potential biomarkers and were used to constructed the CYTOscore. Patients stratified by baseline CYTOscore showed significantly longer OS (HR, 0.31; 95%CI, 0.16-0.62; p= 0.00045) and PFS (HR, 0.33; 95%CI, 0.17-0.62; p= 0.00036) in the low-risk group, which also had higher complete response (CR) rates (66% vs 35%, p=0.014). These finding were next validated in the external cohort, with the low-risk group demonstrating higher CR rates (66% vs 27%, p=0.039) and longer OS (HR 0.30, 95% CI 0.09-0.99, p=0.045). A nomogram incorporating baseline CYTOscore and clinical characteristics showed promising predictive accuracy in 1-, 2-, and 3-year OS (AUC=0.77, 0.78, and 0.76). Multi-omics analysis revealed enriched interferon-γ/α signaling in B cells within low-risk patients. Conclusions: The CYTOscore based on IL-8, CCL3, and CCL4 effectively predicts treatment response and survival in ESCC patients receiving CRT plus anti-PD-1 antibody.
- Open Access
- 1 October 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (10)
Modification of Pathological Nodal Classification for pT1b Esophageal Squamous Cell Carcinoma With Lymphovascular Invasion: Over 10‐Year Experience
Background: Lymphovascular invasion (LVI) adversely affects the survival of pT1b esophageal squamous cell carcinoma (ESCC). It is hypothesized that a modified stage classification of pT1b ESCC based on LVI may facilitate multidisciplinary therapy in LVI‐positive patients. Aims: The study aims to investigate the impact of LVI on pathological nodal classification for pT1b ESCC. Methods and Results: Surgically resected pT1b ESCC patients in Sun Yat‐sen University Cancer Center between 2008 and 2018 were retrospectively reviewed. Tumor sections were re‐assessed for LVI by gastrointestinal pathologists. The associations between patient survival and LVI were evaluated by the Log‐rank method. A multivariate Cox regression model was applied to identify the impact of LVI on survival. Prognostic performance was assessed by Harrell's C ‐index. A total of 424 cases with the pT1b stage were included. The risk of LVI was significantly higher in patients with nodal positive status ( p < 0.001) and larger tumor size ( p = 0.033). The 5‐year OS for LVI+ patients were 50.3% versus 78.0% for LVI− ( p < 0.001). Multivariable analyses suggested that LVI ( p = 0.021) and pN ( p = 0.016) stages were two independent adverse prognostic factors in pT1b patients. When classifying LVI+ as an independent subgroup into the pN category, the modified pN staging system demonstrated a superior prognostic performance ( p < 0.001). Conclusion: Tumors with LVI should be defined as a separate subclassification to accurately classify the prognostic category in pT1b patients. Further studies are required to investigate multidisciplinary therapies for LVI+ pT1b patients.
- 1 October 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (10)
Open AccessModification of Pathological Nodal Classification for pT1b Esophageal Squamous Cell Carcinoma With Lymphovascular Invasion: Over 10‐Year Experience
Background: Lymphovascular invasion (LVI) adversely affects the survival of pT1b esophageal squamous cell carcinoma (ESCC). It is hypothesized that a modified stage classification of pT1b ESCC based on LVI may facilitate multidisciplinary therapy in LVI‐positive patients. Aims: The study aims to investigate the impact of LVI on pathological nodal classification for pT1b ESCC. Methods and Results: Surgically resected pT1b ESCC patients in Sun Yat‐sen University Cancer Center between 2008 and 2018 were retrospectively reviewed. Tumor sections were re‐assessed for LVI by gastrointestinal pathologists. The associations between patient survival and LVI were evaluated by the Log‐rank method. A multivariate Cox regression model was applied to identify the impact of LVI on survival. Prognostic performance was assessed by Harrell's C ‐index. A total of 424 cases with the pT1b stage were included. The risk of LVI was significantly higher in patients with nodal positive status ( p < 0.001) and larger tumor size ( p = 0.033). The 5‐year OS for LVI+ patients were 50.3% versus 78.0% for LVI− ( p < 0.001). Multivariable analyses suggested that LVI ( p = 0.021) and pN ( p = 0.016) stages were two independent adverse prognostic factors in pT1b patients. When classifying LVI+ as an independent subgroup into the pN category, the modified pN staging system demonstrated a superior prognostic performance ( p < 0.001). Conclusion: Tumors with LVI should be defined as a separate subclassification to accurately classify the prognostic category in pT1b patients. Further studies are required to investigate multidisciplinary therapies for LVI+ pT1b patients.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 18
Diagnostic yield using electromagnetic navigation bronchoscopy for peripheral pulmonary nodules <2 cm
Background: Although electromagnetic navigation bronchoscopy (ENB) is highly sensitive in the diagnosis of peripheral pulmonary nodules (PPNs), its diagnostic yield for subgroups of smaller PPNs is under evaluation. Objectives: Diagnostic yield evaluation of biopsy using ENB for PPNs <2 cm. Design: The diagnostic yield, sensitivity, specificity, positive predictive value, and negative predictive value of the ENB-mediated biopsy for PPNs were evaluated. Methods: Patients who had PPNs with diameters <2 cm and underwent ENB-mediated biopsy between May 2015 and February 2020 were consecutively enrolled. The final diagnosis was made via pathological examination after surgery. Results: A total of 82 lesions from 65 patients were analyzed. The median tumor size was 11 mm. All lesions were subjected to ENB-mediated biopsy, of which 29 and 53 were classified as malignant and benign, respectively. Subsequent segmentectomy, lobectomy, or wedge resection, following pathological examinations were performed on 64 nodules from 57 patients. The overall sensitivity, specificity, positive predictive value, and negative predictive value for nodules <2 cm were 53.3%, 91.7%, 92.3%, and 51.2%, respectively. The receiver operating curve showed an area under the curve of 0.721 ( p < 0.001). Additionally, the sensitivity, specificity, positive predictive value, and negative predictive value were 62.5%, 100%, 100%, and 42.9%, respectively, for nodules with diameters equal to or larger than 1 cm; and 30.8%, 86.7%, 66.7%, and 59.1%, respectively, for nodules less than 1 cm. In the subgroup analysis, neither the lobar location nor the distance of the PPNs to the pleura affected the accuracy of the ENB diagnosis. However, the spiculated sign had a negative impact on the accuracy of the ENB biopsy ( p = 0.010). Conclusion: ENB has good specificity and positive predictive value for diagnosing PPNs <2 cm; however, the spiculated sign may negatively affect ENB diagnostic accuracy. In addition, the diagnostic reliability may only be limited to PPNs equal to or larger than 1 cm.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 18
Open AccessDiagnostic yield using electromagnetic navigation bronchoscopy for peripheral pulmonary nodules <2 cm
Background: Although electromagnetic navigation bronchoscopy (ENB) is highly sensitive in the diagnosis of peripheral pulmonary nodules (PPNs), its diagnostic yield for subgroups of smaller PPNs is under evaluation. Objectives: Diagnostic yield evaluation of biopsy using ENB for PPNs <2 cm. Design: The diagnostic yield, sensitivity, specificity, positive predictive value, and negative predictive value of the ENB-mediated biopsy for PPNs were evaluated. Methods: Patients who had PPNs with diameters <2 cm and underwent ENB-mediated biopsy between May 2015 and February 2020 were consecutively enrolled. The final diagnosis was made via pathological examination after surgery. Results: A total of 82 lesions from 65 patients were analyzed. The median tumor size was 11 mm. All lesions were subjected to ENB-mediated biopsy, of which 29 and 53 were classified as malignant and benign, respectively. Subsequent segmentectomy, lobectomy, or wedge resection, following pathological examinations were performed on 64 nodules from 57 patients. The overall sensitivity, specificity, positive predictive value, and negative predictive value for nodules <2 cm were 53.3%, 91.7%, 92.3%, and 51.2%, respectively. The receiver operating curve showed an area under the curve of 0.721 ( p < 0.001). Additionally, the sensitivity, specificity, positive predictive value, and negative predictive value were 62.5%, 100%, 100%, and 42.9%, respectively, for nodules with diameters equal to or larger than 1 cm; and 30.8%, 86.7%, 66.7%, and 59.1%, respectively, for nodules less than 1 cm. In the subgroup analysis, neither the lobar location nor the distance of the PPNs to the pleura affected the accuracy of the ENB diagnosis. However, the spiculated sign had a negative impact on the accuracy of the ENB biopsy ( p = 0.010). Conclusion: ENB has good specificity and positive predictive value for diagnosing PPNs <2 cm; however, the spiculated sign may negatively affect ENB diagnostic accuracy. In addition, the diagnostic reliability may only be limited to PPNs equal to or larger than 1 cm.